Literature DB >> 1903910

Susceptibility of Neisseria gonorrhoeae to cefpodoxime: determination of MICs and disk diffusion zone diameters.

T Fekete1, J Woodwell, K R Cundy.   

Abstract

We studied the susceptibilities of 77 strains of Neisseria gonorrhoeae to four antibiotics: cefpodoxime, ceftriaxone, penicillin, and tetracycline. All strains were susceptible to ceftriaxone. Cefpodoxime MICs (range, 0.001 to 0.125 micrograms/ml) were parallel to and approximately four times those of ceftriaxone, and all strains will probably be considered susceptible to cefpodoxime. Disk diffusion zone diameters for cefpodoxime ranged from 35 to 57 mm. Of the strains, 32% were penicillin resistant and 51% were tetracycline resistant (MIC, greater than or equal to 2 micrograms/ml). Susceptibility measurements were consistent for disk diffusion zone diameter and MIC, with an overall agreement of 215 of 225 (96%) for ceftriaxone, penicillin, and tetracycline combined. On the basis of these in vitro data, cefpodoxime should be evaluated in the treatment of gonorrhea.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1903910      PMCID: PMC245038          DOI: 10.1128/AAC.35.3.497

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  In vitro activity of cefpodoxime proxetil (U-76,252; CS-807) against Neisseria gonorrhoeae.

Authors:  R D Schaadt; B H Yagi; G E Zurenko
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

2.  Frequency and distribution in the United States of strains of Neisseria gonorrhoeae with plasmid-mediated, high-level resistance to tetracycline.

Authors:  J S Knapp; J M Zenilman; J W Biddle; G H Perkins; W E DeWitt; M L Thomas; S R Johnson; S A Morse
Journal:  J Infect Dis       Date:  1987-04       Impact factor: 5.226

3.  The in-vitro activity of cefpodoxime: a comparison with other oral cephalosporins.

Authors:  R Wise; J M Andrews; J P Ashby; D Thornber
Journal:  J Antimicrob Chemother       Date:  1990-04       Impact factor: 5.790

4.  Susceptibility to cephalosporins of penicillin-susceptible and penicillin-resistant strains of Neisseria gonorrhoeae from Philadelphia.

Authors:  T Fekete; D A Serfass; S C Lafredo; K R Cundy
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

5.  Oral ciprofloxacin versus ceftriaxone for the treatment of urethritis from resistant Neisseria gonorrhoeae in Zambia.

Authors:  J P Bryan; S K Hira; W Brady; N Luo; C Mwale; G Mpoko; R Krieg; E Siwiwaliondo; C Reichart; C Waters
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

6.  Gonococcal resistance to antibiotics.

Authors:  C S Easmon
Journal:  J Antimicrob Chemother       Date:  1985-10       Impact factor: 5.790

7.  Pharmacokinetics of cefpodoxime in plasma and skin blister fluid following oral dosing of cefpodoxime proxetil.

Authors:  M T Borin; G S Hughes; C R Spillers; R K Patel
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

8.  Standardization of disk diffusion and agar dilution susceptibility tests for Neisseria gonorrhoeae: interpretive criteria and quality control guidelines for ceftriaxone, penicillin, spectinomycin, and tetracycline.

Authors:  R N Jones; T L Gavan; C Thornsberry; P C Fuchs; E H Gerlach; J S Knapp; P Murray; J A Washington
Journal:  J Clin Microbiol       Date:  1989-12       Impact factor: 5.948

9.  Antibacterial activities of cefpodoxime, cefixime, and ceftriaxone.

Authors:  C C Knapp; J Sierra-Madero; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1988-12       Impact factor: 5.191

Review 10.  The identification and antimicrobial susceptibility testing of Neisseria gonorrhoeae, 1980-1987. Results from the College of American Pathologists Microbiology Surveys Program.

Authors:  R N Jones; D C Edson
Journal:  Arch Pathol Lab Med       Date:  1988-05       Impact factor: 5.534

View more
  3 in total

Review 1.  Antimicrobial susceptibility testing of Neisseria gonorrhoeae and implications for epidemiology and therapy.

Authors:  T Fekete
Journal:  Clin Microbiol Rev       Date:  1993-01       Impact factor: 26.132

Review 2.  Cefpodoxime proxetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.

Authors:  J E Frampton; R N Brogden; H D Langtry; M M Buckley
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

Review 3.  Worldwide susceptibility rates of Neisseria gonorrhoeae isolates to cefixime and cefpodoxime: a systematic review and meta-analysis.

Authors:  Rui-xing Yu; Yueping Yin; Guan-qun Wang; Shao-chun Chen; Bing-jie Zheng; Xiu-qin Dai; Yan Han; Qi Li; Guo-yi Zhang; Xiangsheng Chen
Journal:  PLoS One       Date:  2014-01-31       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.